Skip to main navigation

Overview
Corporate
News & Events
Stock Information
Financial Information
- SEC Filings
- Quarterly Results
IR Resources

News & Events

News Releases

News Releases

All
2026
2025
2024
2023
2022
2021
2020
2019

2024.09.16

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

2024.08.29

Adagene to Participate in Investor Conferences in September

2024.07.25

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update

2024.07.12

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

2024.05.22

Adagene to Present at Investor Conferences in June

Pagination

First page
Previous page
…
Page 4
Page 5
Page 6
Page 7
Current page 8
Page 9
Page 10
Page 11
Page 12
…
Next page
Last page

Displaying 36 - 40 of 112

Shareholder Tools

© 2026 Adagene Inc.

Footer Bottom

Home
Privacy
Terms of Use
Contact
Site Credits
LinkedIn